Latest News

Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

June 1st 2025

The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.

Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC
Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC

June 1st 2025

Michiel Van der Heijden, MD, PhD
Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC

June 1st 2025

EV plus pembrolizumab doubles CR rate vs chemotherapy in la/mUC
EV plus pembrolizumab doubles CR rate vs chemotherapy in la/mUC

June 1st 2025

Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

June 1st 2025

Latest News

© 2025 MJH Life Sciences

All rights reserved.